On Monday, NASDAQ: DCPH received an 869 percent higher call option, specifically 601 calls from stock market investors. There have been interesting developments for Deciphera Pharmaceuticals Inc since then. The daily average call options are 62. 

What Do Stock Market Analysts Say About NASDAQ: DCPH?

On 8th October, during. Thursday report, Deciphera Pharmaceuticals received a rating of “hold” from BidaskClub. JPMorgan Chase & Co also issued a rating of “neutral” on 14th September during a Monday report. 

Similarly, SVB Leerink increased its target price to $58.00 from $54.00 and issued a rating of “market perform” to NASDAQ: DCPH stock. Zacks Investment Research, on the other hand, decreased its rating of “buy” to a rating of “hold” on 29th July during a Wednesday report. Lastly, ValuEngine increased the Deciphera Pharmaceuticals rating from “hold” to “buy” on 3rd August during a Monday report. 

What Do Stock Market Investors Say About Deciphera Pharmaceuticals? 

Macquarie Group Ltd recently bought NASDAQ: DCPH shares worth $82,000. Similarly, US Bancorp DE raised its Deciphera Pharmaceuticals Holdings by 56 percent. Russell Investments Group Ltd also acquired NASDAQ: DCPH shares worth $172,000 during the 2nd quarter. Public Employees Retirement Association (Colorado) also bought NASDAQ: DCPH shares worth $186,000. Lastly, America’s Investment Partners increased their Deciphera Pharmaceuticals stakes by 94.9 percent. 

It should be noted that 74.64 percent of Deciphera Pharmaceuticals (NASDAQ: DCPH) is under stock market investors and hedge funds.